A quick peek into the report
Table of Contents
1.1 Overview
1.2 Cancer Type
1.3 Technology
1.4 Market Dynamics
1.5 Regulatory-Approved Products
2.1 Europe
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Market Sizing and Forecast
2.1.3.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
2.1.3.1.1 Germany
2.1.3.1.1.1 Market Dynamics
2.1.3.1.1.2 Market Sizing and Forecast
2.1.3.1.2 France
2.1.3.1.2.1 Market Dynamics
2.1.3.1.2.2 Market Sizing and Forecast
2.1.3.1.3 U.K.
2.1.3.1.3.1 Market Dynamics
2.1.3.1.3.2 Market Sizing and Forecast
2.1.3.1.4 Italy
2.1.3.1.4.1 Market Dynamics
2.1.3.1.4.2 Market Sizing and Forecast
2.1.3.1.5 Spain
2.1.3.1.5.1 Market Dynamics
2.1.3.1.5.2 Market Sizing and Forecast
2.1.3.1.6 Rest-of-Europe
2.1.3.1.6.1 Market Dynamics
2.1.3.1.6.2 Market Sizing and Forecast
3.1 Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
3.2 Company Profiles
3.2.1 Agendia Inc.
3.2.1.1 Company Overview
3.2.1.2 Role of Agendia Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
3.2.1.3 Recent Developments
3.2.1.4 Analyst Perception
3.2.2 CENTOGENE N.V.
3.2.2.1 Company Overview
3.2.2.2 Role of CENTOGENE N.V. in the Next-Generation Breast Cancer Diagnostic and Screening Market
3.2.2.3 Financials
3.2.2.4 Recent Developments
3.2.2.5 Analyst Perception
3.2.3 F. Hoffmann-La Roche Ltd.
3.2.3.1 Company Overview
3.2.3.2 Role of F. Hoffmann-La Roche Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
3.2.3.3 Financials
3.2.3.4 Recent Developments
3.2.3.5 Analyst Perception
3.2.4 Sample Company
3.2.4.1 Overview
3.2.4.2 Top Products / Product Portfolio
3.2.4.3 Top Competitors
3.2.4.4 Target Customers
3.2.4.5 Key Personnel
3.2.4.6 Analyst View
3.2.4.7 Market Share
3.2.5 Sample Company
3.2.5.1 Overview
3.2.5.2 Top Products / Product Portfolio
3.2.5.3 Top Competitors
3.2.5.4 Target Customers
3.2.5.5 Key Personnel
3.2.5.6 Analyst View
3.2.5.7 Market Share
3.2.6 Sample Company
3.2.6.1 Overview
3.2.6.2 Top Products / Product Portfolio
3.2.6.3 Top Competitors
3.2.6.4 Target Customers
3.2.6.5 Key Personnel
3.2.6.6 Analyst View
3.2.6.7 Market Share
3.2.7 Sample Company
3.2.7.1 Overview
3.2.7.2 Top Products / Product Portfolio
3.2.7.3 Top Competitors
3.2.7.4 Target Customers
3.2.7.5 Key Personnel
3.2.7.6 Analyst View
3.2.7.7 Market Share
Table 1: Key Questions Answered in the Report
Table 2: Some of the Regulatory-Approved Oncology Molecular Diagnostic Products/Services for Different Types of Solid Tumors
Table 3: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
Table 4: Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
Table 5: Agendia Inc.: Key Services and Features
Table 6: CENTOGENE N.V.: Key Services and Features
Table 7: F. Hoffmann-La Roche Ltd.: Key Products and Features
Figure 1: Worldwide Breast Cancer Statistics (by Region), 2020
Figure 2: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 3: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), $Million, 2022 and 2032
Figure 4: Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
Figure 5: Next-Generation Breast Cancer Diagnostic and Screening Market, Key Development Analysis, January 2019-April 2023
Figure 6: Next-Generation Breast Cancer Diagnostic and Screening Market: Research Methodology
Figure 7: Primary Research Methodology
Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
Figure 9: Top-Down Approach (Segment-Wise Analysis)
Figure 10: Oncology Molecular Diagnostic Market, Solid Tumor, $Million, 2022 and 2032
Figure 11: Oncology Molecular Diagnostic Market, Hematological Malignancy, $Million, 2022 and 2032
Figure 12: Oncology Molecular Diagnostic Market, Market Dynamics
Figure 13: Next-Generation Breast Cancer Diagnostic and Screening Market Share (by Region), 2022-2032
Figure 14: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
Figure 15: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 16: Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
Figure 17: Germany Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 18: France Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 19: U.K. Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 20: Italy Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 21: Spain Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 22: Rest-of-Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 23: Agendia Inc.: Product Portfolio
Figure 24: CENTOGENE N.V.: Product Portfolio
Figure 25: CENTOGENE N.V.: Overall Financials, $Million, 2019-2021
Figure 26: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2019-2021
Figure 27: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2019-2021
Figure 28: CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021
Figure 29: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 30: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2020-2022
Figure 31: F. Hoffmann-La Roche Ltd.: Net Revenue (by Segment), $Million, 2020-2022
Figure 32: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2020-2022
Europe Next-Generation Breast Cancer Diagnostic and Screening Market Report Coverage:
|
Europe Next-Generation Breast Cancer Diagnostic and Screening Market |
|||
|
Base Year |
2023 |
Market Size in 2023 |
$0.84 Billion |
|
Forecast Period |
2023-2032 |
Value Projection and Estimation by 2032 |
$2.57 Billion |
|
CAGR During Forecast Period |
13.20% |
|
|
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.
Some of the prominent names in this market are:
• Agendia Inc.
• CENTOGENE N.V.
• F. Hoffmann-La Roche Ltd.
How can this report add value to an organization?
Growth/Marketing Strategy: The Europe next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the Europe next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.
Competitive Strategy: Key players in the Europe next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.
Introduction to Europe Next-Generation Breast Cancer Diagnostic and Screening Market:
The Europe next-generation breast cancer diagnostic and screening market was valued at $0.84 billion in 2023 and is expected to reach $2.57 billion by the end of 2032, registering a CAGR of 13.20% during the forecast period 2023-2032. The growth in the next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.
Market Introduction
The European Next-Generation Breast Cancer Diagnostic and Screening Market is experiencing significant growth driven by factors such as the region's early adoption of advanced medical technologies, a high prevalence of breast cancer, and a strong healthcare infrastructure. European countries prioritize breast cancer awareness and screening, fostering the integration of innovative biomarkers and genetic testing into diagnosis. Collaborations between healthcare institutions, research organizations, and industry players further enhance diagnostic accuracy and efficiency, contributing to improved patient outcomes. These efforts reflect the region's commitment to addressing breast cancer challenges and are expected to sustain market growth and enhance breast cancer management in Europe.
Market Segmentation:
Segmentation 1: by Country
• Germany
• France
• U.K.
• Italy
• Spain
• Rest-of-Europe
Europe Next-Generation Breast Cancer Diagnostic and Screening Market
Analysis and Forecast, 2023-2032
Frequently Asked Questions
The companies developing next-generation genomic and molecular-based assays for breast cancer diagnosis and screening or looking to leverage such assays in the field of oncology (breast cancer) should buy this report. Academic and research institutes working on the development of such assays/techniques for breast cancer can also buy this report.
The global next-generation breast cancer diagnostic and screening market was valued at $3,137.4 million in 2022 and is anticipated to reach $9,880.1 million by 2032, witnessing a CAGR of 12.57% during the forecast period 2023-2032.
Next-generation breast cancer diagnosis and screening refer to advanced methods and technologies for detecting and diagnosing breast cancer. This includes high-resolution imaging techniques, molecular biomarkers, and genomics-based approaches that enable earlier and more accurate breast cancer detection and personalized treatment strategies, ultimately improving patient outcomes.
Prominent market trends include the utilization of liquid biopsy methods for breast cancer diagnosis and the full automation of next-generation diagnostic techniques.
Next-generation breast cancer diagnostic and screening methods offer advantages over traditional approaches by providing earlier detection, higher accuracy, and the ability to tailor treatments based on individual patient profiles. These methods enhance patient outcomes, reduce unnecessary procedures, and contribute to more effective and personalized breast cancer care.